Combined activation of the energy and cellular-defense pathways may explain the potent anti-senescence activity of methylene blue  by Atamna, Hani et al.
Redox Biology 6 (2015) 426–435Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
Abbre
NAO, 10
cotinam
riboside
n Corr
E-mjournal homepage: www.elsevier.com/locate/redoxCombined activation of the energy and cellular-defense pathways may
explain the potent anti-senescence activity of methylene blue
Hani Atamna a,b,n, Wafa Atamna b, Ghaith Al-Eyd a, Gregory Shanower b, Joseph M. Dhahbi c
a College of Medicine, California University of Science & Medicine, Colton, CA 92324, USA
b Department of Basic Sciences, The Commonwealth Medical College (TCMC), Scranton, PA 18509, USA
c Department of Biochemistry, University of California at Riverside, 92521, USAa r t i c l e i n f o
Article history:
Received 12 August 2015
Received in revised form
4 September 2015
Accepted 7 September 2015
Available online 10 September 2015
Keywords:
Mitochondria
Oxidants
Complex-IV
NAD
AMPK
Senescence
Telomeresx.doi.org/10.1016/j.redox.2015.09.004
17/& 2015 The Authors. Published by Elsevier
viations: MB, methylene blue; NAD, nicotina
-nonyl acridine orange; AMPK, AMP-activated
ide phosphoribosyltransferase; AICAR, 5-Ami
esponding author.
ail address: atamnah@calmedu.org (H. Atamna b s t r a c t
Methylene blue (MB) delays cellular senescence, induces complex-IV, and activates Keap1/Nrf2; how-
ever, the molecular link of these effects to MB is unclear. Since MB is redox-active, we investigated its
effect on the NAD/NADH ratio in IMR90 cells. The transient increase in NAD/NADH observed in MB-
treated cells triggered an investigation of the energy regulator AMPK. MB induced AMPK phosphoryla-
tion in a transient pattern, which was followed by the induction of PGC1α and SURF1: both are inducers
of mitochondrial and complex-IV biogenesis. Subsequently MB-treated cells exhibited 4100% increase
in complex-IV activity and a 28% decline in cellular oxidants. The telomeres erosion rate was also sig-
niﬁcantly lower in MB-treated cells. A previous research suggested that the pattern of AMPK activation
(i.e., chronic or transient) determines the AMPK effect on cell senescence. We identiﬁed that the anti-
senescence activity of MB (transient activator) was 8-times higher than that of AICAR (chronic activator).
Since MB lacked an effect on cell cycle, an MB-dependent change to cell cycle is unlikely to contribute to
the anti-senescence activity. The current ﬁndings in conjunction with the activation of Keap1/Nrf2
suggest a synchronized activation of the energy and cellular defense pathways as a possible key factor in
MB's potent anti-senescence activity.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The process of cell senescence is considered to be protective
against cancer because senescent cells have limited proliferative
capacity [1]. Furthermore, accumulating evidence indicates that
senescent cells increase in aging and they are believed to con-
tribute to the process of aging [1–15]. A signiﬁcant slowing in the
age-related deterioration has been observed in mouse model en-
gineered for eliminating senescent cells [2,3]. As the cell senesces
it accumulates biochemical and morphological changes and loses
its function [16]. Furthermore, senescent cells secrete speciﬁc
factors (e.g., cytokines) that could affect the integrity of the ex-
tracellular matrix and may also interfere with the adjacent cells in
their vicinity [1,17–19]. Thus, preventing or delaying the formation
of senescent cells may provide a viable strategy for modulating theB.V. This is an open access article u
mide adenine dinucleotide;
protein kinase; NAMPT, Ni-
noimidazole-4-carboxamide
a).process of cellular senescence and the deleterious effects of se-
nescent cells [20,21]. Along the line of this hypothesis, strategies
such as genetic manipulations or development of speciﬁc drugs
that lack side effects (e.g., promoting cancer) could be promising
for reducing the load of senescent cells and modulating the de-
leterious effects of senescent cells in vivo.
Several compounds have been reported with various abilities of
delaying cell senescence in vitro [20,22]. Recent ﬁndings show that
methylene blue (MB, a redox active agent) is very effective in
delaying cell senescence [23]. At very low concentration (100 nM)
MB prolonged the lifespan of human embryonic lung ﬁbroblasts
(IMR90) by E50% [23]. The anti-senescence activity of MB was
demonstrated in the large gain in Population Doubling Level (PDL)
as well as in prolonging the replicative capacity of the cells by four
to six weeks beyond the control [23]. These observations are in-
triguing since MB has been used in clinical settings for many years
to treat a variety of ailments not related to aging [24,25]. MB could
serve as a candidate drug to test anti-senescence therapy in re-
search models. Therefore, the more we understand the effect of
MB on the intermediary metabolism of the cell the better we
understand the process of cellular senescence delay by MB.
MB is mostly used for treating congenital or poison-inducednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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carrier that transfers electrons from nicotinamide adenine dinu-
cleotides (NAD(P)H) to methemoglobin (Feþ3), which is then re-
duced to deoxyhemoglobin (Feþ2). Thus, the electron shuttling by
MB restores the ability of hemoglobin-heme to bind oxygen [26].
In this process MB oxidizes NAD(P)H to NAD (or NADP) via cellular
dehydrogenases (e.g., cytochrome b5 reductase). Additional stu-
dies suggest that the effect of MB on cell metabolism is con-
centration dependent. At low concentrations (nanomolar range)
MB improves mitochondrial respiration [23,27] and delays cellular
senescence [23]. It increases subunit II of cytochrome c oxidase
(complex IV) by 430%; the rate of heme synthesis; iron uptake;
cell resistance to oxidants (e.g., H2O2); induces the cytoprotective
pathway Keap1/Nrf2 [23, 28]; and prevents cellular senescence
induced by chronic exposure to oxidants [23]. At high concentra-
tion (4micromolar) MB inhibits nitric oxide synthase [29], gua-
nylyl cyclase [30], and causes down regulation of complex IV [23].
At low concentration MB induces complex IV and activates
Keap1/Nrf2 (cytoprotective pathway) [23,28], however the mole-
cular mechanism that drives these changes and their connection
to cell senescence is not clear. Mitochondrial dysfunction, im-
pairment to energy metabolism, telomeres erosion, and oxidative
stress are factors that contribute to cellular senescence [31–35]. In
the current study we concentrated on the effect of MB on complex
IV. We measured the effect of MB on NAD/NADH, which led to
investigating the energy-sensing kinase AMP-activated Protein
Kinase (AMPK). MB induces PGC1α and SURF1, which is important
for mitochondrial and complex IV biogenesis. The ﬁndings of this
study in conjunction with the activation of Keap1/Nrf2 pathway by
MB [23,28] led to investigating the status of reactive oxygen spe-
cies and telomeres erosion in MB-treated cells. The current study
provides molecular correlates to the effect of low concentration of
MB on complex IV, energy metabolism, redox metabolism, and
telomeres.2. Materials and methods
2.1. Material
Cell culture reagents (DMEM, FBS, PenStrep, and trypsin-EDTA),
as well as western blot reagents include NuPAGE 4–12% Bis-Tris
Gel and MOPS SDS Running Buffer (20X) were from Life-Technol-
ogies (Grand Island, NY). NAO and DAPI were from Molecular
Probes (Eugene, Oregon). DCFH, cytochrome c, n-Dodecyl-beta-
maltoside, and DTT were from Sigma (St. Louis, MO). 5-Aminoi-
midazole-4-carboxamide riboside (AICAR) was from Cayman
chemical company (Ann Arbor, MI). The antibodies for AMPK
(AMP-activated protein kinase) and pAMPK (rabbit monocloncal
anti-Phospho-Thr172-AMPKα), PGC1α, SIRT1, phospho-Ser47-
SIRT1 (p-SIRT1) were from Cell Signaling Technology (Beverly,
MA). Antibodies for SURF1 and Actin were from Santa Cruz Bio-
technology (Dallas, TX). Protease inhibitors, phosphatase in-
hibitors, and RIPA buffer with EDTA were from Boston BioProducts
(Ashland, MA). Pierce ECL Western blotting Substrate and Restore
Western blot Stripping Buffer were from Thermo Scientiﬁc
(Rockford, IL). Quick Start Bradford Dye Reagent for protein
quantiﬁcation was from Bio-Rad (Hercules, CA).
2.2. IMR90 cell culture, treatment with MB, and preparing cellular
lysate
Normal human lung ﬁbroblasts (IMR90) were obtained from
Coriell Institute for medical research (Camden, NJ). The cells were
cultured in DMEM supplemented with 10% FBS [23]. IMR90 cells
can be maintained under tissue culture conditions for about threemonths until the replicative senescence is reached, which is
usually at population doubling level (PDL) around 60. The optimal
concentration of MB that delays cell senescence was established as
100 nM [23]. Thus, in the current study we used 100 nM MB.
Newly seeded cell cultures were treated with 100 nM MB for the
speciﬁed intervals as indicated below. At the completion of the
treatment with MB, the cultures were harvested and used to
prepare cell lysates as described below or stored for later use in
80 °C.
2.3. Measuring the weekly gain in population doubling level (PDL)
Cellular replicative senescence was determined by measuring
the weekly gain in PDL and the ﬁnal cumulative PDL as described
previously [23]. Brieﬂy, a week from seeding, the cultures of
IMR90 cells were harvested by trypsinization, and the cells were
counted using Coulter Counter (BeckmanCoulter, Brea CA). The
seeding of a new cell culture was performed by transferring
0.5 million cells from the current cell culture to a new plate.
Several plates can be seeded at once. After a week from seeding,
the new culture was harvested; the cells were counted and new
cultures were seeded again as described above. Every week, the
gain in PDL was calculated by using the initial (0.5 million) and the
ﬁnal cell counts (i.e. densities) as described previously [23]. The
new weekly gain in PDL was added to the previous PDL to estab-
lish the cumulative PDL number. As the cumulative PDL of the
speciﬁc IMR90 cell culture increases, the culture approaches se-
nescence. At senescence the PDL plateaus. Thus, young cells have
low PDL (between 20 and 30) and the ﬁnal PDL of old-senescent
cells usually plateaus at PDLZ55. Senescence was deﬁned when
the cell culture stops gaining PDLs. IMR90 cells were contentiously
maintained in culture until they senesce, which usually lasts three
months.
2.4. Measuring the ratio oxidized to reduced nicotinamid adenine
dinucleotides (NAD/NADH)
The levels of NAD and NADH were measured using EnzyChrom
NAD/NADH Assay Kit (E2ND-100; BioAssay Systems, Hayward,
CA). IMR90 cells were grown in the presence or absence of 100 nM
MB for 0–24 h, harvested, and the cells were collected in ice-cold
PBS. About 105 cells were used to assay NAD and NADH as de-
scribed by the manufacturer. Brieﬂy, two separate sets of 105 cells
were used. One set was extracted by 100 ml NAD-extraction buffer
for NAD determination while the other set was extracted by
NADH-extraction buffer for NADH determination. Both extracts
were heated for 5 min at 60 °C. The level of NAD and NADH was
assayed using enzymatic recycling of MTT followed by measuring
the change in absorbance at 565 nm at the time points 0 and
15 min using Molecular Devices Spectra MaxM5. In conjunction
with the unknown samples a standard curve was similarly pre-
pared as described by the manufacturer. NAD and NADH con-
centrations were calculated using the difference in absorbance at
0 and 15 min and the standard curve. The concentration of NAD
and NADH were used to calculate the ratio NAD/NADH at each
time point.
2.5. SDS-PAGE and western blot analysis for speciﬁc protein factors
At the harvesting time point, the IMR90 cell culture plates were
placed on ice, the used media was removed, and the cells were
rinsed three times with ice-cold PBS (Caþ2, Mgþ2-free). The cells
were then scrapped using cell scraper, collected using ice-cold
centrifuge, the supernatant was discarded, and the pellet was re-
suspended into RIPA buffer that was previously supplemented
with phosphatase and protease inhibitors. This cell suspension
H. Atamna et al. / Redox Biology 6 (2015) 426–435428was sonicated at 4 °C and the protein were quantiﬁed using
Bradford reagent. The samples to be analyzed were resolved in (4–
12%) SDS-PAGE, transferred to PVDF membrane (Immobilon-P,
Millipore, Billerica, MA), and blocked with 5% BSA. The PVDF
membranes were developed by incubation with the speciﬁc pri-
mary antibodies: pAMPK, AMPK, PGC1α, SURF1, Actin, p-SIRT1, or
SIRT1 overnight at 4 °C. After washing the primary antibody, the
membrane was exposed to the respective secondary antibody. The
free secondary antibody was then washed and the protein band-
associated-HRP with ECL was used to highlight the protein content
of each band by capturing the chemiluminescence on x-ray ﬁlm.
Actin was used as a loading control for PGC1α and SURF1 while
pAMPK and pSIRT1 were normalized to AMPK and SIRT1, respec-
tively. The pixels density of each band was determined using Im-
age J software. In the case of pAMPK and p-SIRT1, the PVDF
membrane was ﬁrst developed for pAMPK (or p-SIRT1) and then
stripped and redeveloped for the parent proteins AMPK and SIRT1.
2.6. Comparing the anti-senescence activity of MB and AICAR
The effect of AICAR on PDL (i.e., cell senescence) was in-
vestigated using 50 and 100 mM. The concentrations of AICAR were
determined based on a pilot experiment, in which we identiﬁed
the nontoxic concentration of AICAR. We found that 50 and
100 mM AICAR are not cytotoxic to IMR90 cells, thus we used these
concentrations to test the effect of AICAR on cell senescence and
compare to MB. MB was prepared fresh every week in ddw and
added to the growth media at a ﬁnal concentration of 100 nM [23].
AICAR was prepared as 250 mM stock solution, sterilized, and
stored as aliquots in 80 °C. The PDL in control, MB-treated, and
AICAR-treated IMR90 cells was calculated as described in the
section on cell senescence that was described above.
2.7. Measuring the activity of cytochrome c oxidase (complex IV) in
IMR90 cells
IMR90 cells were treated for different intervals with 100 nM
MB and the activity of complex IV was measured using cyto-
chrome c oxidase assay kit (Sigma, St. Louis, MO). Brieﬂy, the lysate
from MB-treated cells or controls were prepared into ice-cold PBS
that was previously supplemented with protease inhibitors as well
as 2 mM n-dodecyl-beta maltoside. The samples were sonicated in
cold and spun down at 4000 RPM for 5 min (Microfuge 22R cen-
trifuge). Complex IV assay buffer contained 10 mM Tris HCl/
120 mM KCl, 0.3 mM n-Dodecyl beta-D-maltoside, pH 7. Ferricyto-
chrome c (2.7 mg is dissolved into 1 ml DDW) was reduced to
ferrocytochrome c by adding 5 mM DTT. Complete reduction of
ferricytochrome c to ferrocytochrome c was conﬁrmed by the in-
crease in its absorbance at 550 nm. Complex IV activity assay re-
quires mixing 30 ml of the lysate with 570 ml assay buffer in a
cuvette, which is then used to blank the spectrophotometer
(Beckman Coulter DU 800) at 550 nm. The enzymatic activity
starts by adding 30 ml of ferrocytochrome c to the cuvette followed
by quick mixing and monitoring the decline in the absorbance at
550 nm (Beckman Coulter DU 800). The ﬁnal concentration of
ferrocytochrome c was 10.4 μM. Complex IV oxidizes ferrocyto-
chrome c to ferricytochrome c causing a decline in the absorbance
at 550 nm. The rate of the decline at 550 nm was measured from
the ﬁrst 20 s of the enzymatic reaction and used with the mM
extinction coefﬁcient ε550¼21.84 [mM]1 [cm]1 of reduced cy-
tochrome c to calculate complex IV activity.
2.8. Staining mitochondrial inner membrane with 10-nonyl acridine
orange (NAO)
NAO is a ﬂuorescent dye that binds with cardiolipin, which isfound only in the mitochondrial inner membrane [36,37]. Thus,
the level of intracellular ﬂuorescence of NAO is an indicator of the
mass of the mitochondrial inner membrane. IMR90 cells were
cultured, treated with MB, and harvested as described above. The
cells were counted using Beckman's Coulter counter and one
million cells were transferred to FACS tubes, spun down at
3000 RPM (Allegra X-22R centrifuge), the supernatant media was
decanted, and the cell pellet was resuspended into two ml of
25 mM HEPES (pH 7.2)/DMEM. A stock solution of 5 mM NAO was
prepared into DMSO. NAO was added to each sample at a ﬁnal
concentration of 200 nM, mixed, and incubated at 37 °C in dark for
30 min. NAO-stained cells were then spun down, the media-con-
taining NAO was decanted, and the cells were washed twice with
Hank's buffer and resuspended in 1 ml Hank's buffer. NAO-stained
cells were analyzed with FACSariaII (FACSariaII, BD, San Jose, CA)
using excitation 490 nm and emission 540 nm.
The optimal concentration of 200 nM NAO was determined by
treating IMR90 cells with increasing concentrations of NAO (0–
5 μM) for 30 min at 37 °C. The ﬂuorescence was measured using
FACSariaII and plotted against the concentration of NAO to de-
termine the range of NAO concentrations that produces linear
increase in intracellular ﬂuorescence before it reaches plateau
(Data not shown). The concentration of NAO that provide 50% of
the linear range of NAO ﬂuorescence was used to measure the
inner membrane mass of the mitochondria in IMR90 cells. This
concentration was 200 nM for NAO.
2.9. Measuring the level of oxidants in IMR90 cells using DCFH
2′,7′-dichloroﬂuorescein diacetate (DCFH-DA) is a cell perme-
able molecule that becomes ﬂuorescent (DCF) following its oxi-
dation by reactive oxygen species [38]. IMR90 cells were cultured,
treated with MB, and then harvested as described above. One
million IMR90 cells were added to FACS tubes, spun down at
3000 RPM (Allegra X-22R centrifuge), supernatant media was
decanted, and the cell pellet was resuspended into 2 ml of 25 mM
HEPES (pH 7.3)/DMEM. A stock solution of 5 mM DCFH was pre-
pared in DMSO. DCFH was added to each sample at a ﬁnal con-
centration of 1 mM, mixed, and incubated at 37 °C in dark for
20 min. DCFH-treated cells were then spun down and the media-
containing DCFH was decanted. The cells were then washed twice
with Hank's buffer and resuspended in 1 ml Hank’s buffer. DCFH-
treated cells were analyzed for DCF ﬂuorescence using FACSaria II
at excitation 480 nm and emission 530 nm.
The optimal concentration of DCFH (1 mM) was determined by
treating IMR90 cells for 20 min with increasing concentrations of
DCFH (0–20 μM) and incubated at 37 °C. The ﬂuorescence was
measured and plotted against the concentration of DCFH to de-
termine the concentrations of DCFH that produces linear increase
in intracellular ﬂuorescence before it reaches plateau (Data not
shown). The concentration of DCFH that provides 50% of the linear
range of the ﬂuorescence was chosen and used to measure the
steady-state level of intracellular oxidants in IMR90 cells. This
concentration was 1 mM for DCFH.
2.10. Determining telomeres length in IMR90 cells
IMR90 cells were treated with or without 100 nM MB starting
at PDL E27 and ending at PDL E44 (four weeks in culture). The
cells were split on weekly basis as described above. The DNA was
extracted and used to measure the telomere length. The telomeres
length was determined by using the kit TeloTAGGG Telomere
Length Assay (Roche Life Sciences). The kit utilizes Southern ana-
lysis of terminal restriction fragments (TRF) that were obtained
after digesting the genomic DNA. In brief, DNA was digested by
mixture of restriction enzymes that preserve the sub-telomeric
H. Atamna et al. / Redox Biology 6 (2015) 426–435 429DNA while non-telomeric DNA is digested to low molecular-
weight fragments. The DNA fragments were then separated by gel
electrophoresis followed by transferring the DNA fragments to a
nylon membrane. The blotted DNA fragments were hybridized to a
digoxigenin (DIG)-labeled probe that is speciﬁc for telomeric re-
peats, then incubated with a DIG-speciﬁc antibody covalently
coupled to alkaline phosphatase. The immobilized telomere probe
was visualized by chemiluminescent substrate (CDP-Star) for al-
kaline phosphatase. The molecular DNA standards were used to
determine average TRF length of the telomere smear using the
molecular-weight standard that was included in the kit.
2.11. Determining the cell cycle phases in IMR90 culture
Normal and young IMR90 cells were synchronized utilizing
contact inhibition. Contact inhibition due to conﬂuency is usually
achieved in IMR90 cells at about seven days after seeding. How-
ever, for this experiment the cell culture was allowed to grow for
eleven days to assure that all the cells ceased dividing. Thus, on
day six a fresh growth medium was used to replace the old media.
This approach of synchronization resulted in 495% of the cells in
G1, o4% S, and o1.6% G2. Chemical inhibition of the cell cycle or
deprivation of speciﬁc nutrient was not used for synchronizing
due to the nature of this experiment, where we test the effect of
MB on cell cycle.
In order to determine the effect of MB on cell cycle, theFig. 1. The effect of MB on NAD/NADH ratio. IMR90 cells were cultured in the presenc
cultures the cells were counted and 105 cells were used to assay NADH and NAD with the
and NADH was assayed by enzymatic recycling followed by measuring the change in abso
NAD (center panel) were calculated using a standard curve and those were used to calcu
each was performed in triplicates. Values are Mean7sem (t-test, *Po0.02). B. A repres
NAMPT to Actin calculated from immuneblots similar to the one presented.synchronized cell culture was harvested and re-seeded (0.5 mil-
lion cell/100 mm plate) and treated with 100 nM MB for various
intervals or remained untreated in order to serve as control. At the
end of each interval, MB-treated cells and control cells were har-
vested, spun down at 1200 RPM for ﬁve minutes. The cells were
washed with Caþ þ- and Mgþ þ- free-PBS twice, ﬁxed in 95%
ethanol, and spun down at 2200 RPM for 10 min, and then re-
suspended in PBS. The resuspended cells were counted and
0.2 million cells were transferred into FACS tube. The cells were
once again spun down, PBS was decanted, and the cells were re-
suspended in 0.1% Triton-X100 solution supplemented with
300 nM DAPI and incubated for 30 min at 4 °C. The cells were then
separated and analyzed at excitation 360 nm and emission 460 nm
using FACSAriaII. The data was analyzed for DNA pattern using
ModFit software for cell cycle analysis (Verity Software, Topsham,
ME).2.12. Statistical analysis
Graphing and statistical analysis were performed using Prism
6.0 software (GraphPad, San Diego, CA, USA). Signiﬁcance was
deﬁned at 95% conﬁdence interval when Po0.05.e or absence of 100 nM MB for 0 (control), 0.25, 2, and 24 h. After harvesting the
help of EnzyChrom NAD/NADH Assay Kit as described in Section 2. The level of NAD
rbance at 565 nm at 0 and 15 min. A. The concentration of NADH (upper panel) and
late the ratio NAD/NADH (Lower Panel). Three independent experiments are shown
entative immunoblot depicting the effect of MB on NAMPT as well as the ratio of
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Fig. 3. The effect of MB on the induction of PGC1α. IMR90 cells were seeded and
incubated with 100 nM MB for different intervals. The cells were harvested at each
speciﬁc time point and the cell lysates were prepared and stored at 80 °C. The
proteins were analyzed with western blot using speciﬁc antibodies for PGC1α and
Actin as described in Section 2. The immuneblot image was captured on the x-ray
ﬁlm and the band density was quantiﬁed using ImageJ. A. Shows a representative
immunoblot of PGC1α and Actin. B. Shows the ratio of the densities of PGC1α to
Actin. Shown is the Mean7sem of at least four independent experiments. One-way
ANOVA, Bonferroni's multiple comparisons test (*Po0.05, ***Po0.001).
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3.1. Methylene blue increases the ratios NAD/NADH, pAMPK/AMPK,
and induces PGC1α
Following 15 min of treatment of IMR90 cells with MB the ratio
NAD/NADH increased by 63%, which within 24 h returned to the
control level (Fig. 1). MB did not affect NAMPT, a rate-limiting
enzyme in NAD synthesis (Fig. 1B), indicating no de novo synthesis
of NAD in MB-treated cells. The data are consistent with the
transient increase in NADH oxidation in MB-treated cells (Fig. 1).
The ratio NAD/NADH is a key indicator for the cellular energy and
redox status [39]. Reduced intracellular energy status (high NAD/
NADH ratio) results in AMPK phosphorylation [40], thus we ex-
amined the effect of MB on AMPK. MB increased the phosphor-
ylation of AMPK at Thr-172 (pAMPK) and as a result the ratio
pAMPK/AMPK gradually increased after 1 h of treatment with MB
until reached signiﬁcance after 24 h. pAMPK/AMPK returned to
the level of the control after 48 h (Fig. 2A and B). Since pAMPK is
capable of inducing PGC1α, the time-dependent effect of MB on
PGC1α was also examined. MB induced PGC1α after 24 h of in-
cubation (Fig. 3A and B). However, MB did not affect the protein
level of SIRT1 or p-Ser47-SIRT1 even after 7 days of incubation
(Data not shown).
3.2. The effect of methylene blue on complex IV activity, mitochon-
drial inner membrane, and intracellular oxidants
The induction of PGC1α by MB suggests a molecular connection
to mitochondrial biogenesis. We further investigated for a direct
connection to complex IV by studying the effect of MB on SURF1, a
key factor in the biogenesis of active complex IV. MB gradually
induced SURF1 over time (Fig. 4A and B) and subsequently the
enzymatic activity of complex IV also increased (Fig. 5). Since
complex IV resides only in the mitochondrial inner membrane, we
decided to examine if the increase in complex IV is accompanied
by an increase in the mitochondrial inner membrane. NAO is a
ﬂuorescent dye that binds cardiolipin, a specialized lipid found
only in the mitochondrial inner membrane. An increase in theCon        1           2          4          20       24         48         72 (hr)
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0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
pA
M
PK
/A
M
PK
(B
an
d
D
en
si
ti e
s)
Con. 1 2 4 20 24 48 72 hr
*
**
*
Fig. 2. The effect of MB on pAMPK/AMPK ratio. IMR90 cells were seeded and in-
cubated with 100 nM MB for different intervals. The cells were harvested at each
speciﬁc time point and the cell lysates were prepared and stored at 80 °C. The
proteins from each time point were analyzed with western blot using speciﬁc
antibodies for pAMPK and AMPK as described in Section 2. The immuneblot image
was captured on the x-ray ﬁlm and the band density was quantiﬁed using ImageJ.
A. Shows a representative immuneblot of pAMPK and AMPK. B. The ratio of pAMPK
to AMPK was calculated from western blots similar to the one in A. Shown the
Mean7sem of at least four independent experiments. One-way ANOVA, Dunnett's
multiple comparisons test, *Po0.05, **Po0.001).
0.00
0.07
0.14
0.21
0.28
0.35
SU
R
F1
/A
ct
in
*
Con. 1 2 4 6 Days
Fig. 4. The effect of MB on SURF1. IMR90 cells were seeded and incubated with
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and the cell lysates were prepared and stored at 80 °C. The proteins were ana-
lyzed with western blot using speciﬁc antibodies for SURF1 and Actin as described
in Section 2. The immuneblot image was captured on the x-ray ﬁlm and the density
of each band was quantiﬁed using ImageJ. A. Shows an immunoblot of SURF1 and
Actin. B. The ratio of the densities of SURF1 to Actin. Shown is the Mean7sem of at
least ﬁve independent experiments. Paired t-test, *po0.04.
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Fig. 5. Time-dependent build-up of cytochrome c oxidase (Complex IV) activity in
response to MB. IMR90 cell cultures were treated with 100 nM MB for increasing
intervals (up to 6 days). At the end of each speciﬁc time point, the cells were
harvested, the lysates were prepared, and complex IV activity was determined as
described in Section 2. The assay buffer contained 10 mM Tris HCl/120 mM KCl,
0.3 mM n-Dodecyl beta-D-maltoside, pH 7. The rate of oxidation of the substrate
ferrocytochrome c to ferricytochrome c was measured at 550 nm and used to
calculate the enzymatic activity with the help of the millimolar extinction coefﬁ-
cient of 21.84. The data are Mean7sem of ﬁve independent experiments.
**Po0.001, One-way ANOVA, Dunn's multiple comparisons test.
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Fig. 6. The effect of MB on the mitochondrial innermembrane. IMR90 cell cultures
were treated with 100 nM MB for increasing intervals up to 7 days. The cultures
were harvested by trypsinazation, counted, and resuspended into DMEM. One
million cells of each time point were placed in designated tube and incubated in
dark with 200 nM NAO. The ﬂuorescence was measured using ﬂow cytometry as
described in Section 2. The data shown are the Mean AFU7SEM of four in-
dependent experiments, each performed in triplicate. *Po0.04, (One-way ANOVA,
Dunnett's multiple comparisons test).
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Fig. 7. The effect of MB on intracellular oxidants. IMR90 cell cultures were treated
with 100 nM MB for increasing intervals (up to 7 days). The cells were harvested by
trypsinazation, counted, and resuspended into 25 mM HEPES (pH 7.3)/DMEM. One
million cells of each speciﬁc time point were placed in the designated tube and
incubated in dark with 1 mM of 2′,7′-dichlorﬂuorescein-diacetate (DCFH-DA) and
the ﬂuorescence of DCF was measured using ﬂow cytometry as described in Section
2. The data shown are the percentages of the Mean AFU7sem of six independent
experiments, each performed in triplicates. *Po0.01, (One-way ANOVA, Dunnett's
multiple comparisons test).
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treated cells as determined by the increase in NAO ﬂuorescence.
NAO ﬂuorescence gradually increased in MB-treated cells in a time
line that was consistent with the increase in complex IV (Fig. 6).
Intracellular incorporation of NAO reached plateau at ﬂuorescence
level 30% above that of the control (Fig. 6).
Elevated activity of complex IV improves mitochondrial re-
spiration [23] and lowers cellular level of oxidants [41–43].
Therefore we measured the level of oxidants in MB-treated cells.
The steady-state level oxidants level in MB-treated cells was 28%
lower than that of the control (Fig. 7). Intracellular oxidants were
determined by using DCFH-DA.
3.3. Methylene blue slows telomeres erosion in IMR90 cells
The rate of telomeres erosion impacts the rate of cellular se-
nescence in dividing cells. Thus, the rate of telomeres erosion wasexamined over four weeks of treatment with MB. The initial PDL
upon seeding of the control and MB-treated group was 27. As
expected, at the end of the four weeks MB-treated cells gained
more PDLs than the controls. The gain in the PDL in weeks 1, 2, 3,
and 4 in the control group was 4, 3.6, 3.5, and 3.4 PDL while the
gain in PDL in the MB-treated group was 4.2, 4.2, 4.3, and 4.3 PDLs,
respectively. The telomeres length was visualized with the help of
Southern blots similar to the one shown in Fig. 8A, which served to
measure the telomeres length in controls and MB-treated cells.
The calculations show that MB-treated IMR90 cells have longer
telomeres as compared to the controls (Fig. 8A). Telomeres erosion
rate was calculated and found to be about 4% per week (0.49 kb/
week) in control cells, while the rate in MB-treated cells was 0.5%/
week (0.03 kb/week) (Fig. 8B, Po0.02).
3.4. Methylene blue does not interfere with the cell cycle of IMR90
cells
Since IMR90 are normal cells, the effect of MB on the cell cycle
was investigated by measuring the distribution of the different
stages of the cell cycle in synchronized IMR90 cell culture. Syn-
chronization by contact inhibition caused more than 95% of the
cells to enter G1 phase (Fig. 9A). The effect of MB on the cell cycle
of the synchronized cultures was examined at 18, 24, 48, and 72 h.
MB did not alter the cell cycle stages regardless of the duration of
exposure to MB. The data presented in Fig. 9B was selected from
IMR90 cells that were exposed to MB for 48 h (Fig. 9B).
3.5. MB is more effective than AICAR in delaying cellular senescence
The anti-senescence activity of AICAR (a chronic activator of
AMPK) was compared to that of MB. The nontoxic concentration of
AICAR was determined based on a pilot experiment, which de-
monstrated 50 mM and 100 mM to be optimal for testing the effect
of AICAR on cell senescence (Data not shown). At 50 mM, AICAR
has no effect on cell senescence (Fig. 10). At 100 mM, on the other
hand, AICAR has positive but small effect on cell senescence
(Fig. 10). The control cultures senesced at PDL 66 (Fig. 10). The gain
in PDL by 100 mM AICAR was 2.1 PDLs (Po0.05) as compared to 18
PDLs (Po0.001) gained by 100 nM MB, which make the ﬁnal PDL
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Fig. 8. The effect of MB on the length of telomeres in IMR90 cells. IMR90 cells were
treated with 100 nM MB starting at PDL 27 and ending at PDL 44. The cells were
split every week, PDL calculated, cultures were re-seeded (0.5 million/plate), and
the remaining cells were collected for DNA extraction as described in Section 2.
Genomic DNA was extracted and processed for telomere length analysis as in-
structed in TeloTAGGG Telomere Length Assay kit. A. Shows Southern blot of
terminal restriction fragments (TRF) after digesting the genomic DNA. B. The rate of
telomeres erosion. The rate was calculated from the Kb distribution of TRF from
three Southern blots similar to the one shown in A. The rate of telomere erosion
was about 0.49 kb/week and 0.03 kb/week in control and MB-treated cells re-
spectively (*Po0.02, t-test).
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Fig. 9. The effect of MB on the cell cycle of IMR90 cells. IMR90, normal human cells,
were synchronized by contact inhibition and used to seed new cultures. One group
of the new cultures was assigned to 100 nM MB while the other group remained as
control. Both groups were incubated for 18, 24, 48, and 72 h. At the end of each
time point the cells were harvested, washed with ice-cold PBS, and prepared for
ﬂow cytometry analysis for the various stages of the cell cycle as described in
Material and Methods. The data from the ﬂow cytometer was used for determining
the distribution of the various stages of cell cycle with the help of ModFit software
(Verity Software, Topsham, ME). A. Shows the synchronization of the cells and the
distribution of the cell cycle stages in 90% conﬂuent culture and in over conﬂuent
H. Atamna et al. / Redox Biology 6 (2015) 426–435432at senescence to be 68.1 and 84 PDLs, respectively (Fig. 10). Thus,
MB causes large gain in total PDL. Furthermore, AICAR prolonged
the interval until the cell culture reached senescence by one week
beyond the control culture while MB prolonged the interval until
the cell culture reached senescence by 6 weeks beyond the control
culture (Fig. 10). It is important to emphasize that the anti-se-
nescence activity of MB requires a concentration that is 1000 times
less than AICAR (100 nM MB vs. 100 mM AICAR).culture. Each time point represents the Mean7sem of three independent experi-
ments, each performed in triplicates. *Po0.05 One-way ANOVA, Friedman test. B.
Shows the distribution of the cell cycle stages in MB-treated and control cultures at
the time point 48 h. Although several intervals were tested, shown are the data
from 48 h incubation with MB (see text for details).4. Discussion
MB is a strong anti-senescence agent that also induces complex
IV [23], however the molecular correlates of these actions are not
clear. In the current study we utilized the fact that MB is a mild
redox agent [44] that receives electrons from NAD(P)H dehy-
drogenases [23,26] and investigated its effect on cellular meta-
bolism with the hope to ﬁnd a possible link to complex IV. Pre-
vious studies suggest that MB is reduced at the cell surface, a
process that increases its diffusibility across the cell [45]. Within
15 min of exposure to MB the NAD/NADH ratio increased by 63%,
which returns to the control level within 2 h (Fig. 1). The increase
in NAD/NADH is driven by an increase in NAD and a decrease in
NADH (Fig. 1), which is likely due to an increase in the oxidation ofNADHþ rather than an increase in NADþ synthesis since MB did
not affect NAMPT, the rate-limiting enzyme in NAD synthesis
(Fig. 1B). The NAD/NADH ratio is an indicator of the energy and
redox status, thus the increase in NAD/NADH suggested a change
to pAMPK/AMPK. An elevated NAD/NADH ratio indicates low cel-
lular energy status, a condition that causes AMPK phosphorylation
[46]. Indeed, the ratio pAMPK/AMPK increases in MB-treated cells,
peaks at 24 h from the exposure to MB, and returns to the control
level after 48 h (Fig. 2). The transient increases in NAD/NADH
(Fig. 1) and pAMPK/AMPK (Fig. 2) suggest that MB causes a tem-
porary change to cellular energy and redox status. The transient
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Fig. 10. Comparing the anti-senescence activity of AICAR to MB. IMR90 cells were
maintained with MB, AICAR, or control until they senesce. The senescence of IMR90
cells was measured by continuously maintaining the cells in culture as described in
Materials and Methods. The control cells gained 66 PDLs and senesced at week 11
(closed squares), 100 nM MB-treated cells gained 84 PDLs and senesced at week 17
(open squares), the 50 mM AICAR-treated cells gained 65.4 PDLs and senesced at
week 11 (closed circles), and 100 mM AICAR-treated cells gained 68.1 PDLs and
senesced at week 12 (open circles). Each time point represents the average of the
PDLs that were calculated from three independent experiments. The data shown is
the Mean7sem. One-way ANOVA, Dunnett's multiple comparisons test. *Po0.05,
***Po0.001.
Scheme 1. MB interacts with AMPK and Keap1/Nrf2 pathways that oversee energy
and cellular defense metabolism, respectively. MB increases the ratio of NAD/
NADH, which connects to the cellular energy regulation (pAMPK) and the cyto-
protective mechanisms (Keap1/Nrf2). The increase in NAD/NADH, which is fast and
transient, is followed by an increase in pAMPK/AMPK. AMPK plays key role in
energy metabolism through mitochondrial and complex IV biogenesis (and activ-
ity). The biogenesis of complex IV requires SURF1 while PGC1α is important for
mitochondrial biogenesis, maintenance, and function. MB also activates the Keap1/
Nrf2 pathway, which plays central role in the defense metabolism against oxidants
and xenobiotic that may damage DNA, lipids, and proteins. The induction of the
cytoprotective mechanism in conjunction with lower levels of oxidants as well as
the induction of complex IV and improvement of mitochondrial respiration are
likely to enhance genome stability and slow telomeres erosion. Black and gray bars
represent mitochondria from young and old cells, respectively. The hexagon re-
presents nucleus from a young cell while dark circle represents the morphological
and heterochromatin changes in old cell.
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the result of a positive feedback that activates speciﬁc pathways
(e.g., of TCA cycle). These pathways work to restore the NAD/NADH
ratio to the control level.
pAMPK activates several metabolic responses. Among the fac-
tors that are affected by pAMPK is the transcriptional coactivator
PGC1α [35,47,48]. PGC1α up-regulates the expression of genes
that are important for mitochondrial biogenesis and maintenance
[40,49] and thus could link MB to the mitochondria and complex
IV. MB induced PGC1α after 24 h of exposure (Fig. 3); which also
parallels the pattern of phosphorylation of AMPK (Fig. 2A). The
increase in PGC1α triggers long-term changes to the mitochondria
[49] such as the induction of complex IV. We found that MB in-
duces SURF1, which is essential for the biogenesis of complex IV
(Fig. 5). Parallel to the increase in SURF1, complex IV activity also
gradually increases starting on day two of treatment and more
than doubled on day ﬁve (Fig. 4). The increase in complex IV ac-
tivity is consistent with the acceleration of mitochondrial re-
spiration by MB [23,27]. The activity of complex IV directly cor-
relates with the energy efﬁciency and inversely with the level of
oxidants [41–43]. The vast majority of intracellular O2 is safely
converted to water by the action of complex IV through mi-
tochondrial respiration. Thus, the induction of complex IV (Fig. 4)
could contribute to the decrease in intracellular oxidants that we
observed in MB-treated cells (Fig. 7). MB also increases the cellular
antioxidants defense mechanisms by activating Nrf2/Keap1 path-
way, enhancing the cellular resistance to oxidative stress [23,28].
The function of Keap1/Nrf2 is impaired with aging or in age-re-
lated disorders [50].
Oxidative stress contributes to telomeres erosion and thus ac-
celerates cell senescence [31–34]. Chronic exposure to low sub-
toxic concentration of H2O2 accelerates cellular senescence [51],
which was prevented by MB [23]. Therefore, we measured the
effect of MB on the rate of telomeres erosion and found it to be
lower in MB-treated cells (Fig. 8). The low erosion rate of telo-
meres is likely contributed for, in part, by lower level of oxidants
(Fig. 7) and the activation of Keap1/Nrf2 pathway by MB [23,28].
Thus, MB could, in part, delay cell senescence by lowing the rate of
telomeres erosion.Because complex IV is located in the inner-membrane of the
mitochondria, the increase in complex IV assembly requires a
concomitant increase in the mass of the mitochondrial inner-
membrane. NAO staining, used to assess the mitochondrial inner-
membrane, shows an increase in the mass of the inner-membrane
in MB-treated cells (Fig. 6). The pattern of the increase in the in-
ner-membrane mass parallels that of complex IV.
The involvement of AMPK in cell senescence is controversial.
AMPK delays cell senescence when induced by acute treatment
with H2O2 [52,53]. However, continuous activation of AMPK has
been proposed to mediate cellular senescence [53,54] and to lead
to adverse effects [55,56]. AICAR shares structural similarity with
AMP, thus it acts as strong activator of AMPK [48,57]. Since MB
transiently activates AMPK we compared its anti-senescence ac-
tivity to AICAR. MB was more than eight times effective in delaying
cell senescence than AICAR (i.e., 18 vs., 2.1 PDLs, respectively,
Fig. 10). Furthermore, MB was six times more effective in
prolonging the replicative capacity of the cell culture than AICAR
(Fig. 10). The reduced efﬁcacy of delaying cell senescence by AICAR
could be, in part, due to the excessive activation of AMPK [53],
which is not the case with MB, which transiently activates AMPK
(Fig. 10). Since cell senescence is measured by determining re-
plicative senescence (the change in PDL), the potential of a direct
effect of MB on cell cycle was examined. Cell cycle analysis of MB-
treated cells shows no affect on cell cycle (Fig. 9). The induction of
the cell defense mechanisms (e.g., Keap1/Nrf2) in conjunction
with the lower levels of oxidants as well as induction of complex
IV and improving mitochondrial respiration are likely to lower
DNA damage and, thus slow telomeres erosion.
Scheme 1 reconciles the various effects of MB from this study
and from published results (e.g., activation of Keap1/Nrf2). We
propose combined activation of energy and cellular defense
pathways by MB as possible key factor in MB’s potent anti-se-
nescence activity. MB alters the ratios NAD/NADH and pAMPK/
AMPK, which leads to the induction of complex IV and lowering
the intracellular oxidants production. In addition, MB activates
Keap1/Nrf2 pathway, which enhances cellular resistance to oxi-
dative stress [23,28]. The activity of Keap1/Nrf2 is attenuated with
age [50], a factor that enhance the damaging impact of oxidants on
macromolecules such DNA and telomeres. Oxidants damage to
H. Atamna et al. / Redox Biology 6 (2015) 426–435434proteins, lipids, and DNA, enhance telomeres erosion, and mi-
tochondrial dysfunction, all are well-established contributing fac-
tors to cell aging [31,58]. These factors are also involved in several
age-related disorders (including Alzheimer disease [59], athero-
sclerosis [60], and Parkinson's disease [61]).
The signiﬁcance of this study lies in the potent anti-senescence
activity of MB as well as in that MB is an FDA-approved drug,
which encourages repurposing its clinical use of low concentration
to delay cell senescence in vivo if the scientiﬁc research supports
this approach. MB is very effective in delaying cellular senescence
in vitro, which makes it an attractive for studying the concept of
anti-senescence therapy in vivo [1,17]. However, the optimal
concentration of MB for in vivo testing needs to be deﬁned [62].
Additional pathological conditions that could beneﬁt from MB
include diabetes and Alzheimer’s disease. Due to its modulatory
effect on AMPK, MB could beneﬁt diabetes patients. Enhancing
mitochondrial activity and complex IV and lowering cellular oxi-
dants production by MB might prevent or delay the onset of mi-
tochondrial dysfunction and energy hypometabolism in Alzhei-
mer’s disease.Conﬂict of interest
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